Ischemic Cerebrovascular Disease
Conditions
Interventions
Healthy Adults Group
:None
Ischemic Cerebrovascular Disease Patients Group:None
Sponsors
The People's Hospital of Dazu, Chongqing
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Confirmed diagnosis: Patients (aged 18–80 years) diagnosed with ischemic stroke (IS) through clinical assessment (NIHSS score) and imaging (cranial CT/MRI-DWI), and who agree to participate in this clinical trial; 2. Large vessel occlusion (internal carotid artery, M1/M2 segment of the middle cerebral artery, basilar artery) confirmed by cerebrovascular angiography (DSA/CTA); 3. Sample collection: Patients undergoing mechanical thrombectomy (stent retrieval and/or aspiration catheter) with successful intraoperative acquisition of intact thrombus specimens (>=1 fragment, diameter >2 mm). The neurointerventional team must assess sample eligibility in real time in the catheterization laboratory; 4. For cardioembolic stroke (e.g., atrial fibrillation, valvular disease, intracardiac thrombus), a history of anticoagulant therapy (INR value/duration of anticoagulant use) must be documented; 5. For large artery atherosclerosis with vascular stenosis >=50% or vulnerable plaque (confirmed by HR-MRI), the intensity of lipid-lowering therapy (LDL-C level) must be recorded; 6. Key time points: Time from symptom onset to femoral artery puncture <=24 hours (anterior circulation) or <=12 hours (posterior circulation); 7. Post-thrombectomy cranial imaging review completed within 24 hours (to exclude hemorrhagic transformation).
Exclusion criteria
Exclusion criteria: 1. Other Stroke Types: Hemorrhagic stroke, cerebral venous sinus thrombosis, or neurological deficits caused by non-ischemic etiologies (e.g., tumor, infection, trauma) confirmed by neuroimaging. 2. Pre-existing Severe Disability: Pre-stroke modified Rankin Scale (mRS) score = 2, indicating significant pre-existing neurological disability. 3. Significant Comorbid Systemic Diseases: Presence of severe cardiac, hepatic, or renal insufficiency (e.g., NYHA Class III-IV heart failure, Child-Pugh Class C liver cirrhosis, end-stage renal disease requiring dialysis), hematological diseases, advanced malignancy, or any other disease with a life expectancy of less than one year. 4. Severe Coagulopathy: Known hereditary or acquired coagulation disorders that cannot be corrected with conventional therapy; Platelet count 70 mL for posterior circulation) or significant mass effect/midline shift. 10. Post-Procedural Hemorrhage: Symptomatic intracranial hemorrhage confirmed by follow-up imaging within 24 hours post-thrombectomy. 11. Exceeding Time Window: Time from symptom onset to femoral artery puncture exceeds the specified windows (>24 hours for anterior circulation or >12 hours for posterior circulation). 12. Inability to Complete Follow-up: Inability to complete the clinical and imaging follow-ups as required by the study protocol due to geographical, social, or psychological reasons. 13. Pregnancy or Lactation: Pregnancy, lactation, or intention to become pregnant within the next 6 months for women of childbearing potential (unless a negative blood/urine pregnancy test is confirmed). 14. Allergy: Documented history of allergy to contrast agents, anesthetics used in the study, or drugs that may be used in subsequent analyses. 15. Participation in Other Clinical Trials: Concurrent participation in another interventional clinical trial that may interfere with the outcome assessment of this study. 16. Impaired Consent: Presence of severe cognitive or psychiatric impairment, or any other condition that precludes the ability to understand and provide written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| antigen presenting cell-like neutrophils;oxidized low density lipoprotein, ox-LDL;inteferon-?,IFN-?; | — |
Countries
China
Contacts
Public ContactTieyi Hu
The People's Hospital of Dazu, Chongqing
Outcome results
None listed